Royalty Pharma plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Royalty Pharma plc
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
A mix of mega-rounds and smaller seed financings show investment happening at both ends of the venture capital spectrum. In public company financings, Gilead prices $2bn note offering, Biogen secures $1.5bn for Reata deal, Inhibrx completes a $200m PIPE and the IPO market shows new signs of life.
Private Company Edition: Genesis raised $200m, Rapport brought in $150m and Cellares closed a $255m round. Also, Ferring got $300m up front in a royalty deal, Fore Biotherapeutics raised a $75m series D and Vaxxas won a $3.67m Wellcome grant to advance a next-generation typhoid vaccine.
Bristol and Regeneron sign separate cell therapy technology pacts, plus deals involving Takeda/ImmunoGen, Serina/AgeX, Cybin/Small Pharma, Taiho/Phost’in, Royalty/Ferring and Aardvark/GRI Bio.
- Other Names / Subsidiaries
- Cypress Bioscience, Inc. (Cellatope Corporation
- Proprius Pharmaceuticals, Inc.)
- Ramius LLC
- Royalty Pharma AG
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.